Zhao Kai

Kai Zhao, Manager,Healthcare analyst and dental medicine professional with 8+ years of experience in clinical research, biotech investment, and market analysis. Bridging medical expertise and business strategy to advance innovation in the healthcare industry. He combines a medical background with investing and research experience across healthcare services and life sciences, focusing on biotech and gene therapy. 

​

At Tenykin Capital, Kai served as an Investment Analyst responsible for sourcing and screening over 100 biotech companies, advancing qualified opportunities through the PE/VC pipeline, and supporting $50 million-plus allocation decisions. He led due diligence on regulatory and reimbursement pathways and built market dashboards tracking U.S. Phase I–III milestones, pricing policy shifts, and IRA impacts to strengthen valuation assumptions and portfolio strategy. 

​

Prior to Tenykin Capital, he supported healthcare equity research at Industrial Securities, covering dental consumables, aligners, and medical devices.

 

Earlier, he trained clinically at Nanjing University Stomatology Hospital, where he participated in over 500 cases and implemented workflow improvements that reduced patient wait times by approximately 20 percent. 

 

Kai brings a rare blend of medical training and financial analysis to evaluate healthcare innovation through both clinical and capital lenses.He integrates deep medical training with strategic and financial perspectives to support evaluation of innovation and investment decision-making.